Cellectar Biosciences, Inc. (CLRB)

In our clinic, evaluating the integration of iopofosine I 131 into our treatment pathways depends heavily on the execution of the confirmatory Phase 3 study. While the ASCO data for relapsed/refractory Waldenström Macroglobulinemia showed a compelling 61.8% major response rate, translating these protocols into standard practice requires flawless site activation and patient enrollment starting in late 2026. We are closely monitoring the trial's progression toward the mid-2027 NDA submission milestone under the FDA's accelerated approval framework.

Watching the cash burn and filing disclosures, I note that despite the successful capital raise, management explicitly flags going concern risks in their Form 10-Q. With Q2 2026 RandD expenses increasing to $4.6 million and a net loss of $6.9 million, the company relies heavily on hitting future clinical milestones to unlock the remaining warrant tranches tied to the pivotal study and NDA acceptance expiring through 2028.

On our desk, the valuation debate centers on whether the 26.86% surge following the oversubscribed May financing has already priced in the near-term catalysts. With $34 million in cash as of June 30, 2026—up significantly from $13.2 million at year-end 2025—the company has secured breathing room via $35 million gross upfront and up to $105 million tied to future milestones like Tranche A and B warrants. However, market sentiment remains sensitive to execution risk and regulatory feedback regarding the confirmatory trial.